National Resilience, Inc. (Resilience), a technology-driven biomanufacturing leader dedicated to broadening access to complex medicines, today announced the expansion of its collaboration with Parvus Therapeutics (“Parvus”) to support the development and manufacturing their second novel autoimmune drug candidate, PVT401, targeting Inflammatory Bowel Disease (IBD).
This announcement follows the successful development and manufacturing of the Parvus clinical-stage drug candidate PVT201 at Resilience. For Resilience, the collaboration represents a significant step toward advancing its mission of improving patient access to complex therapeutics.
“We are proud to deepen our partnership with Parvus Therapeutics to advance the development of PVT401,” said Dr. Susan Billings, Chief Commercial Officer at Resilience. “This collaboration highlights Resilience’s commitment to empowering the development of transformative therapies and delivering manufacturing solutions for complex therapeutics. Together with Parvus, we aim to bring innovative medicines like PVT401 closer to patients, addressing critical unmet needs in autoimmune diseases.”
“Our collaboration with Resilience provided critical development expertise and manufacturing capability we needed to transition from a preclinical to clinical-stage company,” says Louis Demers, Senior Vice President of Technical Operations at Parvus. “We look forward to our working with Resilience to develop our platform technology manufacturing capability and specifically developing PVT401, our second to clinic drug candidate.”
